In correlation with the AhR/CYP1 pathway, Kubi et al. [88] demonstrated an association between the upregulation of HDAC7 and β-cell dysfunction and impaired insulin secretion in hESCs treated with a low dose of the AhR inducer TCDD, suggesting that inhibition of HDAC7 could be a promising targeted therapy for treating T2DM. This evidence concerns the gene AHR and type 2 diabetes mellitus.